• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

丙型肝炎病毒感染患者的工作生产力与临床及患者报告因素的关联

Association of work productivity with clinical and patient-reported factors in patients infected with hepatitis C virus.

作者信息

Younossi Z M, Stepanova M, Henry L, Younossi I, Weinstein A, Nader F, Hunt S

机构信息

Center for Liver Diseases, Department of Medicine, Inova Fairfax Hospital, Falls Church, VA, USA.

Betty and Guy Beatty Center for Integrated Research, Inova Health System, Falls Church, VA, USA.

出版信息

J Viral Hepat. 2016 Aug;23(8):623-30. doi: 10.1111/jvh.12528. Epub 2016 Mar 14.

DOI:10.1111/jvh.12528
PMID:26988765
Abstract

Patients with HCV infection have reduced work productivity (WP), in terms of both presenteeism (impairment in work productivity while working) and absenteeism (productivity loss due to absence from work). The aim of this study was to identify clinical and patient-reported factors that are predictive of WP in HCV-infected patients. HCV-infected patients enrolled in clinical trials completed 3 PRO questionnaires (CLDQ-HCV, SF-36 and FACIT-F) and one work productivity (WPAI:SHP) questionnaire. In employed subjects, work productivity and its absenteeism and presenteeism components were calculated using WPAI:SHP instrument. Of 4121 HCV-infected patients with work productivity data, 2480 (60.2%) reported to be employed, and of those, 2190 had completed all PRO questionnaires before treatment initiation. Of the study cohort, 519/2190 (23.7%) had severe work impairment. In multiple linear regression analysis, work productivity was predicted by lower scores in activity/energy domain of CLDQ-HCV, physical well-being domain of FACIT-F, worry domain of CLDQ-HCV and role physical domain of SF-36 (all P < 0.0005). Furthermore, presenteeism was independently predicted by the activity/energy of CLDQ-HCV, physical well-being of FACIT-F, worry domain of CLDQ-HCV, role physical scale of SF-36 and fatigue scale of FACIT-F (P < 0.002). Finally, absenteeism was independently predicted by physical well-being scale of FACIT-F and role physical scale of SF-36 (all P < 0.002). Clinically, work productivity impairment was predicted by the presence of cirrhosis, anxiety, depression and clinically overt fatigue (P < 0.01). Thus, the most important drivers of WP in HCV are impairment of physical aspects of PROs and clinical history of depression, anxiety, fatigue and cirrhosis.

摘要

丙型肝炎病毒(HCV)感染患者的工作效率会降低,这体现在出勤主义(工作时工作效率受损)和旷工(因缺勤导致的生产效率损失)两方面。本研究的目的是确定可预测HCV感染患者工作效率的临床因素和患者报告因素。参与临床试验的HCV感染患者完成了3份患者报告结局(PRO)问卷(慢性肝病问卷-丙型肝炎病毒(CLDQ-HCV)、36项简明健康状况调查(SF-36)和功能性评估癌症治疗-通用量表(FACIT-F))以及1份工作效率(工作效率和活动障碍问卷:特定健康问题(WPAI:SHP))问卷。在就业受试者中,使用WPAI:SHP工具计算工作效率及其旷工和出勤主义成分。在4121例有工作效率数据的HCV感染患者中,2480例(60.2%)报告有工作,其中2190例在治疗开始前完成了所有PRO问卷。在研究队列中,519/2190(23.7%)有严重的工作障碍。在多元线性回归分析中,工作效率可通过CLDQ-HCV的活动/能量领域、FACIT-F的身体健康领域、CLDQ-HCV的担忧领域和SF-36的角色身体领域得分较低来预测(所有P<0.0005)。此外,出勤主义可通过CLDQ-HCV的活动/能量、FACIT-F的身体健康、CLDQ-HCV的担忧领域、SF-36的角色身体量表和FACIT-F的疲劳量表独立预测(P<0.002)。最后,旷工可通过FACIT-F的身体健康量表和SF-36的角色身体量表独立预测(所有P<0.002)。临床上,工作效率受损可通过肝硬化、焦虑、抑郁和临床明显疲劳的存在来预测(P<0.01)。因此,HCV患者工作效率的最重要驱动因素是PRO身体方面的损害以及抑郁、焦虑、疲劳和肝硬化的临床病史。

相似文献

1
Association of work productivity with clinical and patient-reported factors in patients infected with hepatitis C virus.丙型肝炎病毒感染患者的工作生产力与临床及患者报告因素的关联
J Viral Hepat. 2016 Aug;23(8):623-30. doi: 10.1111/jvh.12528. Epub 2016 Mar 14.
2
Mental and Emotional Impairment in Patients With Hepatitis C is Related to Lower Work Productivity.丙型肝炎患者的精神和情感障碍与较低的工作效率有关。
Psychosomatics. 2016 Jan-Feb;57(1):82-8. doi: 10.1016/j.psym.2015.10.005. Epub 2015 Oct 23.
3
Patient-reported outcomes assessment in chronic hepatitis C treated with sofosbuvir and ribavirin: the VALENCE study.索磷布韦和利巴韦林治疗慢性丙型肝炎的患者报告结局评估:VALENCE 研究。
J Hepatol. 2014 Aug;61(2):228-34. doi: 10.1016/j.jhep.2014.04.003. Epub 2014 Apr 5.
4
Fatigue contributes to work productivity impairment in patients with axial spondyloarthritis: a cross-sectional UK study.疲劳导致中轴型脊柱关节炎患者工作效率受损:一项英国横断面研究。
Clin Exp Rheumatol. 2017 Jul-Aug;35(4):571-578. Epub 2017 Feb 24.
5
Patient-reported outcomes in chronic hepatitis C patients with cirrhosis treated with sofosbuvir-containing regimens.索磷布韦方案治疗肝硬化慢性丙型肝炎患者的患者报告结局。
Hepatology. 2014 Jun;59(6):2161-9. doi: 10.1002/hep.27161. Epub 2014 Apr 30.
6
Impact of age, sex, physical function, health-related quality of life, and treatment with adalimumab on work status and work productivity of patients with ankylosing spondylitis.年龄、性别、身体功能、健康相关生活质量以及阿达木单抗治疗对强直性脊柱炎患者工作状态和工作生产力的影响。
J Rheumatol. 2010 Feb;37(2):385-92. doi: 10.3899/jrheum.090242. Epub 2009 Dec 1.
7
Patient-reported outcomes in patients chronic viral hepatitis without cirrhosis: The impact of hepatitis B and C viral replication.慢性病毒性肝炎非肝硬化患者的患者报告结局:乙型肝炎和丙型肝炎病毒复制的影响。
Liver Int. 2019 Oct;39(10):1837-1844. doi: 10.1111/liv.14171. Epub 2019 Jul 2.
8
Work productivity in relapsing multiple sclerosis: associations with disability, depression, fatigue, anxiety, cognition, and health-related quality of life.复发型多发性硬化症患者的工作生产力:与残疾、抑郁、疲劳、焦虑、认知和健康相关生活质量的关联。
Value Health. 2012 Dec;15(8):1029-35. doi: 10.1016/j.jval.2012.07.010. Epub 2012 Oct 25.
9
Improvement of health-related quality of life and work productivity in chronic hepatitis C patients with early and advanced fibrosis treated with ledipasvir and sofosbuvir.聚乙二醇干扰素α-2a 联合利巴韦林治疗慢性丙型肝炎的病毒学应答预测因素分析
J Hepatol. 2015 Aug;63(2):337-45. doi: 10.1016/j.jhep.2015.03.014. Epub 2015 Mar 17.
10
Effects of sofosbuvir-based treatment, with and without interferon, on outcome and productivity of patients with chronic hepatitis C.基于索磷布韦的治疗(有和无干扰素)对慢性丙型肝炎患者结局和生产力的影响。
Clin Gastroenterol Hepatol. 2014 Aug;12(8):1349-59.e13. doi: 10.1016/j.cgh.2013.11.032. Epub 2013 Dec 6.

引用本文的文献

1
Global Elimination of HCV-Why Is Poland Still So Far from the Goal?全球消除 HCV——为什么波兰仍如此之远?
Viruses. 2023 Oct 9;15(10):2067. doi: 10.3390/v15102067.
2
Efficacy and safety of elbasvir/grazoprevir treatment for Chinese patients with hepatitis C virus genotype 1b: a retrospective study.艾尔巴韦/格拉瑞韦治疗中国丙型肝炎病毒1b型患者的疗效与安全性:一项回顾性研究
Am J Transl Res. 2022 Jun 15;14(6):3995-4005. eCollection 2022.
3
Trends of the Global Hepatitis C Disease Burden: Strategies to Achieve Elimination.全球丙型肝炎疾病负担趋势:消除策略。
J Prev Med Public Health. 2021 Jul;54(4):251-258. doi: 10.3961/jpmph.21.151. Epub 2021 Jun 24.
4
Health-related quality of life and fatigue in patients with chronic hepatitis C with therapy with direct-acting antivirals agents interferon-free.慢性丙型肝炎患者直接作用抗病毒药物无干扰素治疗的健康相关生活质量和疲劳。
PLoS One. 2020 Aug 19;15(8):e0237005. doi: 10.1371/journal.pone.0237005. eCollection 2020.
5
Economic evaluation of the hepatitis C elimination strategy in Greece in the era of affordable direct-acting antivirals.在可负担得起的直接抗病毒药物时代,希腊丙型肝炎消除策略的经济评估。
World J Gastroenterol. 2019 Mar 21;25(11):1327-1340. doi: 10.3748/wjg.v25.i11.1327.
6
Hepatitis C elimination: challenges with under-diagnosis and under-treatment.丙型肝炎消除:诊断不足和治疗不足带来的挑战。
F1000Res. 2019 Jan 14;8. doi: 10.12688/f1000research.15892.1. eCollection 2019.
7
Quality of life of Brazilian chronic hepatitis C patients treated with interferon-free therapies.接受无干扰素疗法治疗的巴西慢性丙型肝炎患者的生活质量。
Rev Inst Med Trop Sao Paulo. 2018 Nov 14;60:e72. doi: 10.1590/S1678-9946201860072.
8
Sofosbuvir/Velpatasvir for the treatment of Hepatitis C Virus infection.索磷布韦/维帕他韦用于治疗丙型肝炎病毒感染。
Acta Biomed. 2018 Oct 8;89(3):321-331. doi: 10.23750/abm.v89i3.7718.